DP
OMCL icon

Dundas Partners’s Omnicell OMCL Stock Holding History

Dundas Partners’s Portfolio OMCL Stock Details OMCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,365
Closed -$155K – 54
2022
Q2 		$155K Hold
1,365
– – 0.02% 49
2022
Q1 		$177K Hold
1,365
– – 0.02% 50
2021
Q4 		$214K Buy
1,365
+1,340
+5,360% +$232K 0.03% 45
2021
Q3 		$4K Buy
+25
New +$3.83K ﹤0.01% 48

Other funds holding OMCL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Dundas Partners's OMCL Position: Q3 2022 in Review

Dundas Partners sold out of Omnicell (OMCL) in Q3 2022, closing a stake of 1,365 shares — an estimated $155K sold.

Dundas Partners first reported a position in OMCL in Q3 2021 and held it in 4 quarters. The position peaked at $214K in Q4 2021. 374 funds tracked by Wall St. Rank hold OMCL as of Q3 2022.

  • Dundas Partners reported no remaining Omnicell position as of Q3 2022 after selling out during the quarter.
  • Dundas Partners sold 1,365 Omnicell shares in Q3 2022, an estimated $155K.
  • Dundas Partners first reported a position in Omnicell in Q3 2021 and held it in 4 quarters.
  • Dundas Partners's Omnicell position peaked at $214K in Q4 2021.
  • 374 funds tracked by Wall St. Rank held Omnicell as of Q3 2022.

Based on Dundas Partners's 13F filing for Q3 2022, filed 14 Nov 2022.